CN103409511A - 阿尔茨海默病的诊断和治疗 - Google Patents

阿尔茨海默病的诊断和治疗 Download PDF

Info

Publication number
CN103409511A
CN103409511A CN2013102808899A CN201310280889A CN103409511A CN 103409511 A CN103409511 A CN 103409511A CN 2013102808899 A CN2013102808899 A CN 2013102808899A CN 201310280889 A CN201310280889 A CN 201310280889A CN 103409511 A CN103409511 A CN 103409511A
Authority
CN
China
Prior art keywords
snp
gene
chromosome
disease
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013102808899A
Other languages
English (en)
Chinese (zh)
Inventor
J·威廉姆斯
M·J·欧文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College Cardiff Consultants Ltd
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0911539A external-priority patent/GB0911539D0/en
Priority claimed from GB0913357A external-priority patent/GB0913357D0/en
Priority claimed from GB0917326A external-priority patent/GB0917326D0/en
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Publication of CN103409511A publication Critical patent/CN103409511A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2013102808899A 2009-07-03 2010-06-22 阿尔茨海默病的诊断和治疗 Pending CN103409511A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0911539.5 2009-07-03
GB0911539A GB0911539D0 (en) 2009-07-03 2009-07-03 Diagnosis of alzheimer's disease
GB0913357.0 2009-07-31
GB0913357A GB0913357D0 (en) 2009-07-31 2009-07-31 Diagnosis of alzheimer's disease
GB0917326.1 2009-10-03
GB0917326A GB0917326D0 (en) 2009-10-03 2009-10-03 Diagnosis of alzheimer's disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800292599A Division CN102471800A (zh) 2009-07-03 2010-06-22 阿尔茨海默病的诊断和治疗

Publications (1)

Publication Number Publication Date
CN103409511A true CN103409511A (zh) 2013-11-27

Family

ID=43014386

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800292599A Pending CN102471800A (zh) 2009-07-03 2010-06-22 阿尔茨海默病的诊断和治疗
CN2013102808899A Pending CN103409511A (zh) 2009-07-03 2010-06-22 阿尔茨海默病的诊断和治疗

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2010800292599A Pending CN102471800A (zh) 2009-07-03 2010-06-22 阿尔茨海默病的诊断和治疗

Country Status (8)

Country Link
US (3) US20120122703A1 (enExample)
EP (2) EP2449134B1 (enExample)
JP (2) JP5917395B2 (enExample)
CN (2) CN102471800A (enExample)
AU (1) AU2010267835C1 (enExample)
CA (1) CA2766876C (enExample)
NZ (1) NZ596614A (enExample)
WO (1) WO2011001135A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106290823A (zh) * 2016-10-18 2017-01-04 上海凯璟生物科技有限公司 一种阿尔兹海默综合症标志物abca7检测试剂盒和制备方法
CN114736963A (zh) * 2022-05-25 2022-07-12 首都医科大学宣武医院 一种用于预测阿尔茨海默病发病风险的物质的组合、试剂盒及应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2449134B1 (en) * 2009-07-03 2016-07-27 University College Cardiff Consultants Limited Diagnosis and treatment of alzheimer's disease
WO2011024035A1 (en) * 2009-08-27 2011-03-03 Institut Pasteur De Lille Method for determining the risk of occurrence of alzheimer's disease
GB201212334D0 (en) * 2012-07-11 2012-08-22 Warwick The Therapeutic targets for alzheimers disease
CN104102839B (zh) * 2013-11-16 2017-10-27 西安电子科技大学 一种基于多尺度网格曲面形状特征的阿尔茨海默病脑皮层自动分类方法
CN105969885A (zh) * 2016-06-24 2016-09-28 江苏雄鸣医药科技有限公司 一种阿尔兹海默症的基因诊断试剂盒
CN106978475A (zh) * 2016-08-17 2017-07-25 上海易瑞生物科技有限公司 一种阿尔茨海默氏病易感基因检测分型试剂盒及其应用
US11725232B2 (en) * 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
WO2018157014A1 (en) * 2017-02-24 2018-08-30 Duke University Metabolic biomarkers for the identification and characterization of alzheimer's disease
CN110249061A (zh) * 2017-05-15 2019-09-17 英孚美迪泰克株式会社 与阿尔茨海默病风险相关的apoe启动子单核苷酸多态性及其用途
KR101933847B1 (ko) 2017-05-15 2018-12-28 조선대학교산학협력단 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도
WO2018212371A1 (ko) * 2017-05-17 2018-11-22 조선대학교산학협력단 알츠하이머병 위험도와 관련된 apoe 프로모터 단일염기변이 및 이것의 용도
JP7112660B2 (ja) * 2018-03-13 2022-08-04 アイ２ディーエックス インコーポレイテッド 個別化医療における情報の電子配信
CN112424600B9 (zh) * 2018-05-18 2024-07-02 阿纳韦克斯生命科学公司 σ-1激动剂治疗的优化和受治疗者的筛选方法
CN110607364B (zh) * 2019-11-01 2023-04-28 北京中医药大学 通过检测snp位点确定等位基因的基因型的方法
KR102561438B1 (ko) * 2020-11-04 2023-07-28 사회복지법인 삼성생명공익재단 뇌 아밀로이드 베타 축적 가능성을 예측하는 방법
JP7731540B2 (ja) * 2021-03-26 2025-09-01 国立研究開発法人農業・食品産業技術総合研究機構 アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット
CN117136234A (zh) * 2021-04-13 2023-11-28 国立大学法人京都大学 信息处理方法、信息处理装置以及程序
CL2021001380A1 (es) 2021-05-26 2022-01-14 Corporacion Centro Int De Biomedicina Icc Generación de un nuevo anticuerpo monoclonal sitio específico para la proteína tau y su uso como herramienta en biomarcadores específicos para la detección temprana de enfermedades neurodegenerativas y patologías involucradas con la proteína tau como alzheimer y otras demencias.
KR102775636B1 (ko) * 2022-03-15 2025-03-05 사회복지법인 삼성생명공익재단 유럽 인구 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법
KR20250125708A (ko) * 2024-02-15 2025-08-22 이화여자대학교 산학협력단 고인지예비능 생체표지자로서의 snp 및 이의 이용

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
WO2006138716A2 (en) * 2005-06-17 2006-12-28 Brt Laboratories, Inc. Thermodynamically defined gene specific primers
JP2007166962A (ja) * 2005-12-21 2007-07-05 Japan Health Science Foundation アルツハイマー病の予測または診断の方法
WO2008085601A2 (en) * 2006-11-02 2008-07-17 Genizon Biosciences Inc. Genemap of the human genes associated with asthma disease
US20100196895A1 (en) * 2007-04-17 2010-08-05 Shigeru Kinoshita Method for determination of onset risk of glaucoma
EP2449134B1 (en) * 2009-07-03 2016-07-27 University College Cardiff Consultants Limited Diagnosis and treatment of alzheimer's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BERTRAM LARS等: "Genome-wide Association Analysis Reveals Putative Alzheimer"s Disease Susceptibility Loci in Addition to APOE", 《AMERICAN JOURNAL OF HUMAN GENETICS》 *
无: "refSNP ID:rs11136000", 《NCBI DBSNP》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106290823A (zh) * 2016-10-18 2017-01-04 上海凯璟生物科技有限公司 一种阿尔兹海默综合症标志物abca7检测试剂盒和制备方法
CN114736963A (zh) * 2022-05-25 2022-07-12 首都医科大学宣武医院 一种用于预测阿尔茨海默病发病风险的物质的组合、试剂盒及应用

Also Published As

Publication number Publication date
JP2014012007A (ja) 2014-01-23
JP5917395B2 (ja) 2016-05-11
WO2011001135A2 (en) 2011-01-06
EP2891723B1 (en) 2017-10-04
US20150119264A1 (en) 2015-04-30
JP5917460B2 (ja) 2016-05-18
JP2012531195A (ja) 2012-12-10
HK1169455A1 (en) 2013-01-25
CA2766876C (en) 2020-01-28
WO2011001135A3 (en) 2011-06-30
AU2010267835A1 (en) 2011-12-15
EP2449134B1 (en) 2016-07-27
CN102471800A (zh) 2012-05-23
EP2449134A2 (en) 2012-05-09
AU2010267835B2 (en) 2014-11-06
US20120122703A1 (en) 2012-05-17
NZ596614A (en) 2012-11-30
EP2891723A1 (en) 2015-07-08
WO2011001135A9 (en) 2011-02-24
US20130288906A1 (en) 2013-10-31
CA2766876A1 (en) 2011-01-06
AU2010267835C1 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
CN103409511A (zh) 阿尔茨海默病的诊断和治疗
CN103930568A (zh) 用于治疗、诊断和监测阿尔茨海默病的方法
Frick et al. Serum proteomics reveal APOE-ε4-dependent and APOE-ε4-independent protein signatures in Alzheimer’s disease
Peuralinna et al. Genome‐wide association study of neocortical Lewy‐related pathology
US20160102353A1 (en) Polymorphisms Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risk
KR20220072459A (ko) 알츠하이머병 발병 위험도 예측을 위한 단일염기다형성 마커 및 이의 용도
Wachter et al. Landscape of brain myeloid cell transcriptome along the spatiotemporal progression of Alzheimer’s disease reveals distinct sequential responses to Aβ and tau
US8137916B2 (en) Susceptibility gene for alzheimer's disease
US20130157873A1 (en) Methods of assessing a risk of developing necrotizing meningoencephalitis
US9127316B2 (en) Markers associated with Alzheimer'S disease
US8377640B2 (en) Diagnostic screens for Alzheimer's disease
US20140171371A1 (en) Compositions And Methods For The Diagnosis of Schizophrenia
AU2014265063B2 (en) Diagnosis and treatment of Alzheimer's disease
Andersen et al. Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer’s disease
JP2022150707A (ja) アミロイドβ蓄積リスクの有無の指標とする方法、一塩基多型（ＳＮＰ）の存在又は非存在を検出する方法、組成物、及びキット
HK1169455B (en) Diagnosis and treatment of alzheimer's disease
WO2014207246A1 (en) New polymorphisms for the diagnosis of idiopathic scoliosis disease
CN103571854A (zh) Sucla2基因突变体及其应用
Riboldi et al. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson’s disease myeloid cells
van Broeckhoven et al. Alzheimer risk associated with a copy number polymorphism in the complement receptor 1 increasing C3b/C4b binding sites

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20131127